1 |
Shibata W, Maeda S, Hikiba Y, Yanai A, Sakamoto K, Nakagawa H, et al. c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res;68(13):5031-9, 2008.
DOI
|
2 |
Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene;21(33):5038-46, 2002.
DOI
|
3 |
Di R, Huang MT, Ho CT. Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model. J Agric Food Chem;59(13):7474-81, 2011.
DOI
|
4 |
Mitra S, Lee JS, Cantrell M, Van Den Berg CL. C-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem;286(17):15287-97, 2011.
DOI
|
5 |
Kaoud TS, Mitra S, Lee S, Taliaferro J, Cantrell M, Linse KD, et al. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem Biol;6(6):658-66, 2011.
DOI
|
6 |
Kulkarni SA, Krishnan SBB, Chandrasekhar B, Banerjee K, Sohn H, Madhavan T. Characterization of Phytochemicals in Ulva intestinalis L. and Their Action Against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. Front Chem;9(January 2020):1-16, 2021.
|
7 |
Yadalam PK, Varatharajan K, Rajapandian K, Chopra P, Arumuganainar D, Nagarathnam T, et al. Antiviral Essential Oil Components Against SARS-CoV-2 in Pre-procedural Mouth Rinses for Dental Settings During COVID-19: A Computational Study. Front Chem;9(March):1-11, 2021.
|
8 |
Kulkarni SA, Nagarajan SK, Ramesh V, Palaniyandi V, Selvam SP, Madhavan T. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. J Mol Struct;1221, 2020.
|
9 |
Jordaan MA, Ebenezer O, Damoyi N, Shapi M. Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz. Heliyon;6(8): e04642, 2020.
|
10 |
Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell;103(2):239-52, 2000.
DOI
|
11 |
Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: From junk to gold? Nat Rev Drug Discov;2(7):554-65., 2003.
DOI
|
12 |
Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO;15(11):2760-70, 1996.
DOI
|
13 |
Bogoyevitch MA, Ngoei KRW, Zhao TT, Yeap YYC, Ng DCH. c-Jun N-terminal kinase (JNK) signaling: Recent advances and challenges. Biochim Biophys Acta - Proteins Proteomics [Internet] 2010;1804(3):463-75. Available from: http://dx.doi.org/10.1016/j.bbapap.11. 002,2009.
DOI
|
14 |
Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle;2(3):199-201, 2003.
|